Alx Oncology Holdings (ALXO) Short term Debt (2020 - 2026)

Alx Oncology Holdings has reported Short term Debt for 7 years, with the latest figure at $5.2 million in Q1 2026.

• Quarterly Short term Debt rose 200.0% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 200.0% YoY) and the FY2025 annual result came in at $5.2 million, up 1099.31% from the prior year.
• Short term Debt steadied at $5.2 million in Q1 2026 per ALXO's latest filing, from $5.2 million in the prior quarter.
• Over five years, Short term Debt peaked at $5.2 million in Q4 2025 and troughed at $435000.0 in Q4 2024.
• A 5-year average of $2.8 million and a median of $2.6 million in 2022 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2022 and 2025: Short term Debt climbed 1.23% in 2022, then soared 1099.31% in 2025.
• Over 5 years, Short term Debt stood at $1.6 million in 2022, then tumbled by 49.7% to $830000.0 in 2023, then tumbled by 47.59% to $435000.0 in 2024, then jumped by 1099.31% to $5.2 million in 2025, then changed by 0.0% to $5.2 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $5.2 million, $5.2 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.